Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
22 December 2021Website:
http://nexgel.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 19 Nov 2024 21:18:04 GMTDividend
Analysts recommendations
Institutional Ownership
NXGL Latest News
LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 727,272 of its shares of common stock and the issuance of warrants to purchase up to an aggregate of 363,636 shares of common stock for a combined offering purchase price of $2.75 per share of common stock in a registered direct offering. The warrants will have an exercise price of $4.25 per share and be exercisable immediately upon issuance and have a term of five years from the date of issuance.
LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, is scheduled to participate in the following October 2024 investor conferences.
LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board.
LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced record second quarter 2024 revenue of $1.44 million and is reiterating revenue guidance for the 2024 third and fourth quarter of $2.2 million and $2.6 million, respectively.
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
The 30-patient study is designed to measure the efficacy of applying NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatments
LANGHORNE, Pa., July 08, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited revenue for the second quarter of 2024 and has provided revenue guidance for the third and fourth quarter of 2024.
LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the first product to be distributed under its recently formed partnership with STADA Arzneimittel AG (“STADA”), a European leader in consumer health. Histasolv®, sold as DAOSIN® in Europe, is Europe's number one selling Diamine Oxidase (‘DAO') enzyme supplement generating well over $10 million in annualized revenue to treat histamine food intolerance, which can cause migraines and headaches, gut issues, and skin conditions. Headquartered in Germany, STADA is one of the fastest growing top ten companies in consumer healthcare and the fourth largest manufacturer in this segment in Europe.
The acquisition of Silly George expands NEXGEL's consumer product portfolio in Health, Wellness, and Beauty. Silly George is currently generating around $2 million in revenue.
NEXGEL, Inc. (NXGL) Q4 2023 Earnings Call Transcript
What type of business is NexGel Inc Common Stock?
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name. It is also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
What sector is NexGel Inc Common Stock in?
NexGel Inc Common Stock is in the Healthcare sector
What industry is NexGel Inc Common Stock in?
NexGel Inc Common Stock is in the Medical Instruments & Supplies industry
What country is NexGel Inc Common Stock from?
NexGel Inc Common Stock is headquartered in United States
When did NexGel Inc Common Stock go public?
NexGel Inc Common Stock initial public offering (IPO) was on 22 December 2021
What is NexGel Inc Common Stock website?
https://nexgel.com
Is NexGel Inc Common Stock in the S&P 500?
No, NexGel Inc Common Stock is not included in the S&P 500 index
Is NexGel Inc Common Stock in the NASDAQ 100?
No, NexGel Inc Common Stock is not included in the NASDAQ 100 index
Is NexGel Inc Common Stock in the Dow Jones?
No, NexGel Inc Common Stock is not included in the Dow Jones index
When was NexGel Inc Common Stock the previous earnings report?
No data
When does NexGel Inc Common Stock earnings report?
Next earnings report date is not announced yet